Showing 1-9 of 9 results for "".

• 28. Practice Exchange

  https://modernod.com/podcasts/four-eyes/28-practice-exchange/36978/
  Thinking about buying or selling an optometric practice in the U.S.? We sit down with Ryan Kelly from Practice Exchange who shares the company’s years of experience in successfully completing practice transitions for optometrists across the U.S. We ask questions based on the seller's side and the bu
  • Audio
  • Podcast

• Business Book Recommendations of 2024

  https://modernod.com/topics/business/business-book-recommendations-of-2024/38847/
  A curated list of inspiring and motivational reads suggested by Modern Optometry’s board members and contributors.
  • Text

• Elevate Your Practice

  https://modernod.com/topics/business/elevate-your-practice/38037/
  By creating a gatekeeper mentality, ODs can transform their care beyond the routine into the extraordinary.
  • Text

• Tools and Technologies for Patients With Low Vision

  https://modernod.com/topics/technology/tools-and-technologies-for-patients-with-low-vision/38958/
  Taking stock of some of the treatment and management options available for patients with this frustrating condition.
  • Text

• Modern Contact Lens Ordering

  https://modernod.com/topics/contact-lenses/modern-contact-lens-ordering/38494/
  There’s more competition than ever from online retailers, but we can learn from them to better meet our patients where they are.
  • Text

• The Art and Science of Managing Post-LASIK Keratectasia

  https://modernod.com/topics/contact-lenses/the-art-and-science-of-managing-post-lasik-keratectasia/38782/
  When to consider contact lenses versus surgical intervention for the best patient outcomes.
  • Text
• Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunction
  https://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/
  Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
• PECAA Annual Meeting Draws Record Attendance
  https://modernod.com/news/pecaa-annual-meeting-draws-record-attendence/2476621/
  PECAA (Professional Eye Care Associates of America) hosted its sold-out annual meeting May 16-18 at the JW Marriott Austin. The member-only event drew a record 900+ individuals from the PECAA community for a mix of bu
• iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)
  https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/
  iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu